MoonLake Immunotherapeutics (MLTX)
After hours:
- GuruFocus.com
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
Details on Clinical Advances and Financial Health Amidst Ongoing Research and Development Efforts
- GlobeNewswire
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA)
- Business Wire
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland, April 10, 2024--MoonLake Immunotherapeutics ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active
